Effects of Recombinant Factor VIIa on Blood Coagulation in Patients Undergoing Liver Transplantation

李宏
DOI: https://doi.org/10.3760/j.issn:0254-1416.2006.12.019
2006-01-01
Abstract:Objective To evaluate the effects of recombinant factorⅦa (rFⅦa) on blood coagulation in patients undergoing liver transplantation. Methods Twenty ASAⅡorⅢpatients with end-stage liver disease (17 male, 3 female) aged 27-65 yr weighing 53-120 kg undergoing liver transplantation were enrolled in this study. Their liver function was classified as Child-Pugh score B or C. Their preoperative prothrombin time (PT) was 20 seconds and Hb 51-114 g·L-1 . rFⅦa 40-80μg·kg-1 was givenⅣas a bolus 5 min before skin incision. Blood samples were taken from internal jugular vein beforeⅣinjection of rFⅦa (T0 , baseline), at 5, 15, 30, 60 and 120 min after rFⅦa injection (T1-5) , 15 min of anhepatic phase (T6 ) and 30 min of neohepatic phase (T7) for determination of PT, prothrombin activity (PTA), activated partial thromboplastin time (APTT), thrombin time (TT) , international normalized ratio (INR), fibrinogen (Fib), D-dimer and platelet count (PLTs) .Results PT and INR were significantly reduced at T1-6 compared to the baseline at T0 ( P 0.05). APTT was significantly decreased at T2-5 and TT was significantly increased at T7 . There was no significant change in Fib, D-dimer and PLTs during operation as compared with baseline. Conclusion It is possible to reduce intraoperative blood loss and transfusion byⅣrFⅦa administration which can correct coagulation abnormality to some extent in patients undergoing liver transplantation.
What problem does this paper attempt to address?